Platinum-based chemotherapy in triple-negative breast cancer

被引：170

作者：

Sirohi, B. ^{[1
]}

Arnedos, M. ^{[1
]}

Popat, S. ^{[1
]}

Ashley, S. ^{[1
]}

Nerurkar, A. ^{[1
]}

Walsh, G. ^{[1
]}

Johnston, S. ^{[1
]}

Smith, I. E. ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Breast Unit, London SW3 6JJ, England

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 11期

关键词：

breast cancer; early and advanced; platinum chemotherapy; triple-negative;

D O I：

10.1093/annonc/mdn395

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. Patients and methods: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others. Results: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months). Conclusion: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.

引用

页码：1847 / 1852

页数：6

共 33 条

[1] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[2] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[3] Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic locally advanced breast cancer (infusional ECarboF): A very active and well-tolerated outpatient regimen [J].

Bonnefoi, H ;

Smith, IE ;

OBrien, MER ;

Seymour, MT ;

Powles, TJ ;

Allum, WH ;

Ebbs, S ;

Baum, M .

BRITISH JOURNAL OF CANCER, 1996, 73 (03) :391-396

[4] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[5]

Chia K, 2007, ADV BREAST CANC, V4, P75

[6]

*CLINICALTRIALS GO, 2007, CISPL 1 LIN THER TRI

[7] Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study [J].

de Boer, RH ;

Saini, A ;

Johnston, SRD ;

O'Brien, MER ;

Ellis, PA ;

Verrill, MW ;

Prendiville, JA ;

Walsh, G ;

Ashley, S ;

Smith, IE .

BREAST, 2000, 9 (03) :149-155

[8] Triple-negative breast cancer: Clinical features and patterns of recurrence [J].

Dent, Rebecca ;

Trudeau, Maureen ;

Pritchard, Kathleen I. ;

Hanna, Wedad M. ;

Kahn, Harriet K. ;

Sawka, Carol A. ;

Lickley, Lavina A. ;

Rawlinson, Ellen ;

Sun, Ping ;

Narod, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434

[9] Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer [J].

Eisen, T ;

Smith, IE ;

Johnston, S ;

Ellis, PA ;

Prendiville, J ;

Seymour, MT ;

Walsh, G ;

Ashley, S .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1350-1357

[10] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

← 1 2 3 4 →